The governance controversy surrounding the BNC project has reignited. According to reports, YZi Labs recently issued a statement on social media questioning a series of measures taken by CEA Industries (BNC)—particularly the introduction of the poison pill plan and amendments to the bylaws. YZi Labs believes that these measures essentially restrict shareholders' exercise of written consent rights and indirectly strengthen the power of the board of directors, which contradicts the original intention of protecting shareholder rights.

More notably, YZi Labs refuted BNC's claim that "they have never considered an alternative token方案." They pointed out that BNC's CEO David Namdar explicitly mentioned this consideration in January 2025. This discrepancy in statements and information asymmetry further fuels market concerns about the project's transparency.

This tug-of-war at the governance level reflects the internal checks and balances that many Web3 projects face during rapid expansion. The balance between protecting shareholder rights and delineating the powers of the board of directors seems to have become a key issue testing the project's governance capabilities.